Goldman Sachs’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-30,000
| Closed | -$418K | – | 6373 |
|
|
2022
Q3 | $418K | Buy |
+30,000
| New | +$483K | ﹤0.01% | 5091 |
|
|
2020
Q4 | – | Sell |
-20,000
| Closed | -$829K | – | 5778 |
|
|
2020
Q3 | $829K | Buy |
+20,000
| New | +$919K | ﹤0.01% | 4199 |
|
|
2019
Q2 | – | Sell |
-15,500
| Closed | -$1.73M | – | 5411 |
|
|
2019
Q1 | $1.73M | Buy |
+15,500
| New | +$1.69M | ﹤0.01% | 3727 |
|
|
2017
Q1 | – | Sell |
-1,700
| Closed | -$185K | – | 7067 |
|
|
2016
Q4 | $185K | Hold |
1,700
| – | – | ﹤0.01% | 5821 |
|
|
2016
Q3 | $280K | Buy |
1,700
+100
| +6% | +$15.8K | ﹤0.01% | 5530 |
|
|
2016
Q2 | $228K | Sell |
1,600
-400
| -20% | -$58.3K | ﹤0.01% | 5594 |
|
|
2016
Q1 | $257K | Sell |
2,000
-36,700
| -95% | -$4.33M | ﹤0.01% | 5394 |
|
|
2015
Q4 | $5.78M | Buy |
38,700
+26,400
| +215% | +$4.47M | ﹤0.01% | 2696 |
|
|
2015
Q3 | $2.04M | Buy |
12,300
+1,800
| +17% | +$396K | ﹤0.01% | 3775 |
|
|
2015
Q2 | $2.53M | Sell |
10,500
-73,700
| -88% | -$19.6M | ﹤0.01% | 3599 |
|
|
2015
Q1 | $23.7M | Buy |
84,200
+43,400
| +106% | +$9.4M | 0.01% | 1634 |
|
|
2014
Q4 | $6.37M | Sell |
40,800
-10,000
| -20% | -$1.85M | ﹤0.01% | 2765 |
|
|
2014
Q3 | $12M | Buy |
50,800
+26,500
| +109% | +$6.76M | ﹤0.01% | 2214 |
|
|
2014
Q2 | $5.75M | Sell |
24,300
-79,500
| -77% | -$21M | ﹤0.01% | 2881 |
|
|
2014
Q1 | $34.2M | Buy |
+103,800
| New | +$35M | 0.01% | 1329 |
|
Goldman Sachs's ICPT Position: Q4 2023 in Review
Goldman Sachs sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 1,019,073 shares — an estimated $18.9M sold.
Goldman Sachs first reported a position in ICPT in Q1 2014 and held it in 39 quarters. The position peaked at $48.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Goldman Sachs reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Goldman Sachs sold 1,019,073 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $18.9M.
- Goldman Sachs first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 39 quarters.
- Goldman Sachs's Intercept Pharmaceuticals, Inc. position peaked at $48.4M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.